Abstract
Vaccines against COVID-19 based on the mRNA technology have broken many records, from the speed of development and production, to the number of doses administered and have overall proven safe, with only very rare reported adverse events. The accelerated rollout and the permissive regulatory framework had the major caveat that manufacturers did not provide biodistribution and pharmacokinetics data for their products in humans, despite this being essential for interpreting both the dynamics of the immune response and any potential toxic effects. Thankfully, in the past two years, the scientific community has attempted to fill the gaps, which will undoubtedly help in fine-tuning the next generation of mRNA vaccines. Here we review existing data on the biodistribution and pharmacokinetics of the commercially available mRNA vaccine platforms, focusing on human studies, where available. We structure this review by tissue type and we discuss potential correlations between vaccine mRNA uptake and pathogenic effects, if applicable. We find that many studies have focused on the heart, due to the medical and social impact of myocarditis, especially in adolescents. We conclude by observing critical data is still missing for many organs and we suggest potential avenues for future research.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
